News | April 06, 2015

Volcano Receives CE Mark for iFR Scout Pullback Software

Extension of iFR Modality software helps diagnose serial lesions and diffuse coronary disease

iFR Scout, pullback software, iFR Modality, fractional flow reserve, FFR

iFR Modality screenshot courtesy of Volcano Corp.

April 6, 2015 — Royal Philips announced that Volcano, a Philips business, has received CE Mark for the iFR Scout pullback software. iFR Scout is a functional extension of its existing instant wave-Free Ratio (iFR) Modality, optimized to assess serial lesions and diffuse coronary disease. Limited market release will commence immediately at leading European and Japanese medical centers. This software is currently pending 510(k) clearance at the U.S. Food and Drug Administration (FDA), and is not available for sale in the U.S.

The iFR Modality is a physiologic measurement performed using the same Volcano pressure measurement guide wires and equipment used by catheterization labs for fractional flow reserve (FFR), but it avoids the administration of hyperemic agents into the patient that induce stress to the heart to increase blood flow. This allows for a meaningful, lesion-specific assessment in seconds by amplifying the signal at rest.

Physicians have historically used a pressure wire pullback technique with FFR, under hyperemic conditions, to assess the type of underlying disease severity, whether focal or diffuse, to help determine the appropriate treatment for the patient. With the iFR Scout pullback software, this same functionality to 'scout out' the most treatable lesions will now be available without the administration of a hyperemic agent, thereby potentially reducing procedural time and cost to the facility, as well as improving patient comfort.

"Up to now, many operators felt uncomfortable in the frequent scenario of FFR interrogation in vessels with more than one stenosis, as interpretation is more difficult, and intravenous infusion is mandatory for FFR pullbacks," stated Javier Escaned, M.D., consultant interventional cardiologist at Hospital Clinico San Carlos, Madrid, Spain. "The great attractiveness of iFR pullback is that resting flow is much more constant, and stable in these cases, allowing for more predictable interpretation of results. Further, we will now be able to conduct pullback without the need for administration of hyperemic agents. This may contribute to a wider adoption of physiological vessel mapping and, therefore, to a better, tailored treatment of patients with multiple coronary stenoses."

For more information: www.volcanocorp.com

Related Content

Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
Overlay Init